Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.

Pride NA, Barton B, Hutchins P, Coghill DR, Korgaonkar MS, Hearps SJC, Rouel M, Malarbi S, North KN, Payne JM.

BMJ Open. 2018 Aug 30;8(8):e021800. doi: 10.1136/bmjopen-2018-021800.

2.

Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Chisholm AK, Anderson VA, Pride NA, Malarbi S, North KN, Payne JM.

Neuropsychol Rev. 2018 Sep;28(3):317-340. doi: 10.1007/s11065-018-9380-x. Epub 2018 Aug 11.

PMID:
30097761
3.

The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study.

Pride NA, Korgaonkar MS, North KN, Barton B, Payne JM.

Cortex. 2017 Aug;93:1-11. doi: 10.1016/j.cortex.2017.04.022. Epub 2017 May 6.

PMID:
28554066
4.

Impaired engagement of the ventral attention system in neurofibromatosis type 1.

Pride NA, Korgaonkar MS, North KN, Payne JM.

Brain Imaging Behav. 2018 Apr;12(2):499-508. doi: 10.1007/s11682-017-9717-8.

PMID:
28364401
5.

Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome.

O'Grady GL, Verschuuren C, Yuen M, Webster R, Menezes M, Fock JM, Pride N, Best HA, Benavides Damm T, Turner C, Lek M, Engel AG, North KN, Clarke NF, MacArthur DG, Kamsteeg EJ, Cooper ST.

Neurology. 2016 Oct 4;87(14):1442-1448. Epub 2016 Sep 2.

6.

Theory of mind in children with Neurofibromatosis Type 1.

Payne JM, Porter M, Pride NA, North KN.

Neuropsychology. 2016 May;30(4):439-48. doi: 10.1037/neu0000262. Epub 2016 Jan 11.

PMID:
26752121
7.

Early History of Chronic Obstructive Pulmonary Disease 1808-1980.

Watson RA, Pride NB.

COPD. 2016;13(2):262-73. doi: 10.3109/15412555.2015.1043521. Epub 2015 Sep 29.

PMID:
26418529
8.

Glottal Aperture and Buccal Airflow Leaks Critically Affect Forced Oscillometry Measurements.

Bikov A, Pride NB, Goldman MD, Hull JH, Horvath I, Barnes PJ, Usmani OS, Paredi P.

Chest. 2015 Sep;148(3):731-738. doi: 10.1378/chest.14-2644.

PMID:
25742459
9.

Smoking cessation in COPD causes a transient improvement in spirometry and decreases micronodules on high-resolution CT imaging.

Dhariwal J, Tennant RC, Hansell DM, Westwick J, Walker C, Ward SP, Pride N, Barnes PJ, Kon OM, Hansel TT; †Deceased.

Chest. 2014 May;145(5):1006-1015. doi: 10.1378/chest.13-2220.

10.

Social functioning in adults with neurofibromatosis type 1.

Pride NA, Crawford H, Payne JM, North KN.

Res Dev Disabil. 2013 Oct;34(10):3393-9. doi: 10.1016/j.ridd.2013.07.011. Epub 2013 Aug 2.

PMID:
23911645
11.

The genetic and neuroanatomical basis of social dysfunction: lessons from neurofibromatosis type 1.

Pride NA, Korgaonkar MS, Barton B, Payne JM, Vucic S, North KN.

Hum Brain Mapp. 2014 May;35(5):2372-82. doi: 10.1002/hbm.22334. Epub 2013 Jul 24.

PMID:
23881898
12.

Reply from the authors.

Hughes JM, Pride NB.

Am J Respir Crit Care Med. 2013 Mar 15;187(6):660-1. No abstract available.

PMID:
23614143
13.

Act now against new NHS competition regulations: an open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations.

Davis J, Banks I, Wrigley D, Peedell C, Pollock A, McPherson K, McKee M, Irving WL, Crome P, Greenhalgh T, Holland W, Evans D, Maryon-Davis A, Smyth A, Fleming P, Coleman M, Sharp DJ, Whincup P, Logan S, Cook D, Moore R, Rawaf S, McEewen J, West R, Yudkin JS, Clarke A, Finer N, Domizio P, Bambra C, Jones A, Feder G, Scott-Samuel A, Irvine L, Sharma A, Fitchett M, Boomla K, Folb J, Paul A, McCoy D, Tallis R, Burgess-Allen J, Edwards M, Tomlinson J, Colvin D, Gore J, Brown K, Mitchel S, Lau A, Sayer M, Clark L, Silverman R, Marmot S, Rainbow D, Carter L, Mann N, Fielding R, Logan J, Tebboth L, Arnold N, Stobbart K, Cabot K, Finer S, Edwards M, Davies D, Buttivant H, Kraemer S, Newell J, Griffiths A, Fitzgerald R, Macgibbon R, Lee A, Macklon AF, Hobson E, Jenner D, Jacobson B, Timmis A, Salim A, Evans-Jones J, Caan W, Awsare N, Pride N, Suckling R, Bratty C, Rossiter B, Hawkins D, Currie J, Camilleri-Ferrante C, Fluxman J, Bhatti O, Anson J, Etherington R, Lawrence D, Fell H, Clarke E, Ormerod J, Ormerod O, Ireland M, Duncan JA, Chandy R, Mindell J, Mullen P, Bennett-Richards P, Hirst J, Murphy E, Martin P, Lowes S, Fleming P, Grunewald R, Reeve J, Schweiger M, Coates J, Farrelly G, Chamberlain MA, Lewis G, Young J, Scott B, Gibbs J, Landers A, Deveson P, Ingrams G, Leigh M, Gawler J, Ford A, Nixon J, McCartney M, Bareford D, Singh S, Lockwood K, Cripwell M, Ehrhardt P, Bell D, Wortley P, Tomlinson L, Hotchkiss J, Ford S, Turner G, Reissman G, Lewis D, Johnstone C, Tomson M, Torabi P, Bell D, Tomson D, Tulloch A, Johnston S, Dickinson J, McElderry E, Ross W, Holt K, Logan M, Klonin H, Jenner D, Danby J, Goodger V, Puntis J, Dickson H, Gould DA, Livingstone A, Lefevre D, Kendall B, Singh G, Hall P, Darling J, Hamlyn AN, Patel A, Erskine J, Fisher B, Hughes R, Highton C, Venning H, Singer R, Brearey S, Sikorski J, Paintin D, Feehally J, Savage W, Freud KM, Holt VJ, Gill A, Waterston T, Souza Rd, Hopkinson N, Beadsworth M, Franks A, Daley H, Cullinan P, Basarab A, Folb J, Gurling H, Zinkin P, Kirwin S, Buhrs E, Brown R, West A, Marlowe G, Fellows G, Main J, Applebee J, Koperski M, Jones P, Macfarlane A, Beer N, Mason R, West R, Eisner M, Smailes A, Timms P, Knight D, Jones C, Wesby B, Lyttelton L, Morrison R, Bossano D, Walker J, Davies G, Godfrey P, Wolfe I, Nsutebu E, Stevenson N, Cheeroth S, Miller J, Johnson G, Noor R, Hall A, Bostock D, Michael B, Sharvill J, Macpherson J, Lewis D, Ma R, Middleton J, Jeffreys A, Cole J, Boswell JP, Bury B, Mitchison S, Kinmonth AL, Young G, Maclennan I, Munday P.

BMJ. 2013 Mar 20;346:f1819. doi: 10.1136/bmj.f1819. No abstract available.

14.

Reply: Hooray for the VA/TLC and DL(CO)/VA.

Hughes JM, Pride NB.

Am J Respir Crit Care Med. 2013 Jan 1;187(1):107. No abstract available.

PMID:
23397612
15.

Reconciliation of sequence data and updated annotation of the genome of Agrobacterium tumefaciens C58, and distribution of a linear chromosome in the genus Agrobacterium.

Slater S, Setubal JC, Goodner B, Houmiel K, Sun J, Kaul R, Goldman BS, Farrand SK, Almeida N Jr, Burr T, Nester E, Rhoads DM, Kadoi R, Ostheimer T, Pride N, Sabo A, Henry E, Telepak E, Cromes L, Harkleroad A, Oliphant L, Pratt-Szegila P, Welch R, Wood D.

Appl Environ Microbiol. 2013 Feb;79(4):1414-7. doi: 10.1128/AEM.03192-12. Epub 2012 Dec 14.

16.

The impact of ADHD on the cognitive and academic functioning of children with NF1.

Pride NA, Payne JM, North KN.

Dev Neuropsychol. 2012;37(7):590-600. doi: 10.1080/87565641.2012.695831.

PMID:
23066937
17.

Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?

Payne JM, Arnold SS, Pride NA, North KN.

Dev Med Child Neurol. 2012 Oct;54(10):898-904. doi: 10.1111/j.1469-8749.2012.04357.x. Epub 2012 Jul 28.

18.

Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components.

Hughes JM, Pride NB.

Am J Respir Crit Care Med. 2012 Jul 15;186(2):132-9. doi: 10.1164/rccm.201112-2160CI. Epub 2012 Apr 26. Review.

PMID:
22538804
19.

Relation between trunk fat volume and reduction of total lung capacity in obese men.

Watson RA, Pride NB, Thomas EL, Ind PW, Bell JD.

J Appl Physiol (1985). 2012 Jan;112(1):118-26. doi: 10.1152/japplphysiol.00217.2011. Epub 2011 Sep 22.

20.

Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease.

Paredi P, Goldman M, Alamen A, Ausin P, Usmani OS, Pride NB, Barnes PJ.

Thorax. 2010 Mar;65(3):263-7. doi: 10.1136/thx.2009.120790.

PMID:
20335298
21.

Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes.

Watson RA, Pride NB, Thomas EL, Fitzpatrick J, Durighel G, McCarthy J, Morin SX, Ind PW, Bell JD.

J Appl Physiol (1985). 2010 Jun;108(6):1605-12. doi: 10.1152/japplphysiol.01267.2009. Epub 2010 Mar 18.

22.

Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1.

Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN.

J Child Neurol. 2010 Jul;25(7):834-41. doi: 10.1177/0883073809350723. Epub 2010 Feb 8.

PMID:
20142468
23.

Genome sequences of three agrobacterium biovars help elucidate the evolution of multichromosome genomes in bacteria.

Slater SC, Goldman BS, Goodner B, Setubal JC, Farrand SK, Nester EW, Burr TJ, Banta L, Dickerman AW, Paulsen I, Otten L, Suen G, Welch R, Almeida NF, Arnold F, Burton OT, Du Z, Ewing A, Godsy E, Heisel S, Houmiel KL, Jhaveri J, Lu J, Miller NM, Norton S, Chen Q, Phoolcharoen W, Ohlin V, Ondrusek D, Pride N, Stricklin SL, Sun J, Wheeler C, Wilson L, Zhu H, Wood DW.

J Bacteriol. 2009 Apr;191(8):2501-11. doi: 10.1128/JB.01779-08. Epub 2009 Feb 27.

24.
25.

Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD.

Löfdahl CG, Postma DS, Pride NB, Boe J, Thorén A.

Eur Respir J. 2007 Jun;29(6):1115-9. Epub 2007 Mar 1.

26.

Predictors of COPD symptoms: does the sex of the patient matter?

Watson L, Schouten JP, Löfdahl CG, Pride NB, Laitinen LA, Postma DS; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Eur Respir J. 2006 Aug;28(2):311-8. Epub 2006 May 17.

27.

Projections of COPD in males in The Netherlands.

Pride NB.

Eur Respir J. 2006 Jan;27(1):240-1; author reply 241-2. No abstract available.

28.

Proposal for a multidimensional staging system for chronic obstructive pulmonary disease.

Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N, Macnee W, Jones P, Pride N, Rodriguez-Roisin R, Rossi A, Wanner A.

Respir Med. 2005 Dec;99(12):1546-54.

29.

Ageing and changes in lung mechanics.

Pride NB.

Eur Respir J. 2005 Oct;26(4):563-5. No abstract available.

30.

Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study.

Watson L, Vonk JM, Löfdahl CG, Pride NB, Pauwels RA, Laitinen LA, Schouten JP, Postma DS; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Respir Med. 2006 Apr;100(4):746-53. Epub 2005 Sep 30.

31.

Exhaled nitric oxide from lung periphery is increased in COPD.

Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA.

Eur Respir J. 2005 Jul;26(1):52-9.

32.

Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease.

Osmanliev DP, Joyce H, Watson RA, Pride NB.

Respir Med. 2005 Aug;99(8):1053-60. Epub 2005 Feb 24.

33.

Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.

Kiri VA, Pride NB, Soriano JB, Vestbo J.

Am J Respir Crit Care Med. 2005 Aug 15;172(4):460-4. Epub 2005 May 18.

PMID:
15901610
34.

Flow dependence and repeatability of interrupter resistance in lower airways and nose.

Eiser N, Phillips C, Wooler P, Pride NB, Doré CJ.

Physiol Meas. 2005 Jun;26(3):143-56. Epub 2005 Feb 1.

PMID:
15798291
35.

Postural changes in nasal and pulmonary resistance in subjects with asthma.

Duggan CJ, Watson RA, Pride NB.

J Asthma. 2004 Oct;41(7):701-7.

PMID:
15584628
36.

Postural changes in lung volumes and respiratory resistance in subjects with obesity.

Watson RA, Pride NB.

J Appl Physiol (1985). 2005 Feb;98(2):512-7. Epub 2004 Oct 8.

37.

The use and misuse of Penh in animal models of lung disease.

Bates J, Irvin C, Brusasco V, Drazen J, Fredberg J, Loring S, Eidelman D, Ludwig M, Macklem P, Martin J, Milic-Emili J, Hantos Z, Hyatt R, Lai-Fook S, Leff A, Solway J, Lutchen K, Suki B, Mitzner W, Paré P, Pride N, Sly P.

Am J Respir Cell Mol Biol. 2004 Sep;31(3):373-4. No abstract available.

PMID:
15317683
38.

Inhaled steroids and mortality in COPD: bias from unaccounted immortal time.

Kiri VA, Vestbo J, Pride NB, Soriano JB.

Eur Respir J. 2004 Jul;24(1):190-1; author reply 191-2. No abstract available.

39.

Inspiratory muscle load and capacity in chronic heart failure.

Hart N, Kearney MT, Pride NB, Green M, Lofaso F, Shah AM, Moxham J, Polkey MI.

Thorax. 2004 Jun;59(6):477-82.

40.
41.

The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom.

Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB.

Chest. 2003 Aug;124(2):474-81.

PMID:
12907531
42.

Carbon monoxide transfer coefficient (transfer factor/alveolar volume) in females versus males.

Hughes JM, Pride NB.

Eur Respir J. 2003 Jul;22(1):186-7. No abstract available. Erratum in: Eur Respir J. 2003 Sep;22(3):570.

43.

Inhaled glucocorticoids in COPD: immortal time bias.

Pride NB, Vestbo J, Soriano JB, Kiri VA.

Am J Respir Crit Care Med. 2003 Jul 1;168(1):127. No abstract available.

PMID:
12870509
44.

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group.

Lancet. 2003 Feb 8;361(9356):449-56. Erratum in: Lancet. 2003 May 10;361(9369):1660.

PMID:
12583942
45.

Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database.

Soriano JB, Maier WC, Visick G, Pride NB.

Eur J Epidemiol. 2001;17(12):1075-80.

PMID:
12530765
46.

Effect of pattern and severity of respiratory muscle weakness on carbon monoxide gas transfer and lung volumes.

Hart N, Cramer D, Ward SP, Nickol AH, Moxham J, Polkey MI, Pride NB.

Eur Respir J. 2002 Oct;20(4):996-1002.

47.

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.

Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC.

Eur Respir J. 2002 Oct;20(4):819-25.

48.

Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey.

Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J.

Eur Respir J. 2002 Oct;20(4):799-805.

49.

Diaphragm length during tidal breathing in patients with chronic obstructive pulmonary disease.

Gorman RB, McKenzie DK, Pride NB, Tolman JF, Gandevia SC.

Am J Respir Crit Care Med. 2002 Dec 1;166(11):1461-9. Epub 2002 Sep 11.

PMID:
12406839
50.

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler.

Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV.

Eur Respir J. 2002 Jun;19(6):1058-63.

Supplemental Content

Support Center